St. Jude Medical Inc. (NYSE: STJ) will sponsor a clinical study that will evaluate the cost effectiveness of a method of treating patients with coronary artery disease.
The study will analyze the health and cost effects of Fractional Flow Reserve (FFR), a measure that indicates the severity of blood flow blockages in the coronary arteries, according to a statement from St. Jude. FFR helps physicians better identify which lesions are responsible for a patient’s decreased blood supply in the heart.
The research will evaluate cost savings and health benefits of FFR-guided treatment of coronary artery disease patients for six European countries and Canada, and based on a previous study by St. Jude and country-specific data.
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
St. Jude sells FFR measurement systems under the brand “PressureWire.” Blood flow blockages are typically evaluated via angiography, an X-ray examination of the blood vessels or chambers of the heart.